Navigation Links
Syndax Pharmaceuticals Appoints Arlene Morris as CEO
Date:4/18/2012

WALTHAM, Mass., April 18, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., an oncology company moving into phase 3 having completed randomized, placebo controlled phase 2 studies, announced the appointment of Arlene M. Morris as chief executive officer.  Joanna Horobin, MD will serve as president. 

"Syndax is leading the field of epigenetics—a novel way to control gene regulation—to address unmet needs in cancer due to the problem of resistance," said Dennis Podlesak, chairman of the Syndax board of directors. "With the positive phase 2 randomized, placebo-controlled data and the addition of Arlene Morris to our impressive leadership team, Syndax is well positioned to successfully complete the final phase of clinical development to achieve our goal of providing a new treatment option for women with metastatic breast cancer."

During her eight years as president and CEO at Affymax, Ms. Morris led the company through the development of peginesatide (Omontys®), a strategic collaboration with Takeda and an Initial Public Offering. Prior to Affymax Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counseled biopharmaceutical and biotechnology companies on strategic transactions. Before that she was the senior vice president, business development at Coulter, a biotechnology company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases, where she completed numerous transactions including a $1.0 billion merger between Corixa and Coulter. Ms. Morris began her career at Johnson & Johnson (J&J) as a sales representative rising to vice president of business development. Ms. Morris received her bachelor's degree in biology and chemistry from Carlow College. In addition to Syndax Ms. Morris serves on the board of directors of Neovacs and MediciNova.

"After working with Syndax as a director over the past nine months, I am excited to take a more active role now as we move entinostat forward and secure the financing and personnel required to take this exciting product candidate for breast cancer through the final phase of testing," said Ms. Morris. 

About Syndax
Syndax is a late-stage oncology company supported by top venture capitalists and led by industry experts developing treatments for large markets including metastatic breast and lung cancer. The Company's platform is based on employing epigenetics to overcome the problem of resistance in oncology care. Syndax holds worldwide rights to entinostat, an oral, highly selective histone deacetylase (HDAC) inhibitor, which inhibits cancer-relevant HDAC enzymes which contribute to epigenetic alterations driving cancer growth and drug tolerance. Entinostat's unique pharmacokinetic properties, convenient oral dosing and HDAC selectivity, maximize the opportunity to safely combine with and potentially extend the benefit of proven cancer therapies. Entinostat has demonstrated promising activity in randomized, phase 2 clinical trials in combination with targeted therapies.   For more information please visit www.syndax.com.

Contact Information
E. Blair Schoeb   
Syndax Pharmaceuticals, Inc.                                                     
Tel: 908.277.0386                                                                             
bschoeb@syndax.com 


'/>"/>
SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
2. Syndax Pharmaceuticals to Present at Upcoming Fall Conferences
3. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
4. Syndax Pharmaceuticals to Present at BIO Investor Forum
5. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
7. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
8. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
9. Swedish Bactiguard to Enter Into an Exclusive Distribution Agreement With Cadila Pharmaceuticals
10. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
11. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Oakland, California (PRWEB) , ... March 28, 2017 , ... ... that its flagship product, AllegroGraph , has been named a ‘Champion’ by Bloor ... “AllegroGraph is the highest ranked product in its class, and, thanks to Gruff, it ...
(Date:3/28/2017)... WASHINGTON , March 28, 2017  (AACR17, Booth ... sequencing during the American Association for Cancer Research (AACR) ... in Washington, D.C. , April 1-5, ... expression of thousands of cells at the individual level. ... Experts on-hand at AACR to discuss expanded next ...
(Date:3/28/2017)... HOLLISTON, Mass. , March 28, 2017 ... "Company"), a biotechnology company developing bioengineered organ implants to ... bronchus and trachea, today announced that Jim McGorry, ... 3D Printing and BioEngineering panel at the ... 2017 at 2:30 PM ET in Cambrige, Massachussetts. The ...
(Date:3/28/2017)... 2017 /PRNewswire/ -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) ... safety and clinical data from its phase 1/2 tendon repair ... follicle-derived fibroblasts (RCT-01) as a treatment for Achilles tendinosis. ... The ... profile at 6 months and showed no serious adverse events ...
Breaking Biology Technology:
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , a ... globally, announces significant enhancements to new and core technologies ... New products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity ... technology provides the fastest and most accurate capture software ...
(Date:2/26/2017)... -- Securus Technologies, a leading provider of civil and ... corrections and monitoring, announces the appointment of a ... often, too many offenders return to jail or ... to tackle this ongoing problem and improve the ... significant steps are underway, Securus continues to invest ...
(Date:2/21/2017)... -- Der weltweite Biobanking-Sektor wird bis zum ... mit mehr als 50 Vertretern aus verschiedenen Branchen wurde aber ... diese Prognose zu realisieren. ... Zu den Schwierigkeiten für ... für die Biobank, die Implementierung Zeit sparender Technologien, ein ...
Breaking Biology News(10 mins):